A trial of defactinib (VS-6063) for pleural mesothelioma (COMMAND)

This trial is looking at a drug called defactinib to treat mesothelioma that started in the sheets of tissue covering the lungs (pleural mesothelioma).

Unfortunately, it can be difficult for doctors to treat pleural mesothelioma. You may have chemotherapy, but researchers are looking for ways to improve treatment. In this trial, they are looking at an experimental drug called defactinib.

Defactinib is a type of targeted treatment. It stops signals that mesothelioma cells use to divide and grow.

The trial is comparing defactinib with a dummy drug (placebo). It is for people who have recently had chemotherapy and when they finished this treatment, their mesothelioma had got smaller or stayed the same size. The aims of the trial are to

• Find out if defactinib helps people with pleural mesothelioma more than a dummy drug

• See what effect it has on peoples’ quality of life